DrugDashboards

Sumatriptan and Naproxen Sodium

Sumatriptan and Naproxen Sodium · SUMATRIPTAN SUCCINATE 85 mg/1; NAPROXEN SODIUM 500 mg/1 · Tablet, Film Coated · Oral · Aurobindo Pharma Limited

NDC 65862-0928-36 · 9 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has fallen 40% in a year, to $10.84 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$10.84per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D point of sale (median)$22.93per unitnegotiated price across 62 plans — before rebates · Apr 1, 2026
  • Medicaid generic ceiling (FUL)$11.81per TABweighted avg manufacturer price $6.7481 · Aug 1, 2026109% of what pharmacies pay — higher than 62% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$22.93per unit
middle half $16.22$37.19 · 62 plans · Apr 1, 2026
Est. net of rebates
≈ $22.93
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
1%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$25.00$50.00$75.00Jul 2018Sep 2026$10.84
79 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$325.33
#90 count
$975.98

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$58,172
282 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

25Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 3 active manufacturers+10
  • price down 43% year over year+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for sumatriptan and naproxen sodium (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA207457
TE code
AB
Approval date
Feb 15, 2018
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Sumatriptan and Naproxen Sodium (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Aurobindo Pharma LimitedSUMATRIPTAN SUCCINATE 85 mg/1; NAPROXEN SODIUM 500 mg/1Aug 26, 2026Sep 2, 2026
NorthStar RxLLCSUMATRIPTAN SUCCINATE 85 mg/1; NAPROXEN SODIUM 500 mg/1Aug 26, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.SUMATRIPTAN SUCCINATE 85 mg/1; NAPROXEN SODIUM 500 mg/1Aug 26, 2026Sep 2, 2026
Aurobindo Pharma LimitedSUMATRIPTAN SUCCINATE 500 mg/1; NAPROXEN SODIUM 85 mg/1Jul 22, 2026Aug 19, 2026
NorthStar RxLLCSUMATRIPTAN SUCCINATE 500 mg/1; NAPROXEN SODIUM 85 mg/1Jul 22, 2026Aug 19, 2026
Sun Pharmaceutical Industries, Inc.SUMATRIPTAN SUCCINATE 500 mg/1; NAPROXEN SODIUM 85 mg/1Jul 22, 2026Aug 19, 2026
Aurobindo Pharma LimitedNAPROXEN SODIUM 500 mg/1; SUMATRIPTAN SUCCINATE 85 mg/1Jul 15, 2026Jul 15, 2026
NorthStar RxLLCNAPROXEN SODIUM 500 mg/1; SUMATRIPTAN SUCCINATE 85 mg/1Jul 15, 2026Jul 15, 2026
Sun Pharmaceutical Industries, Inc.NAPROXEN SODIUM 500 mg/1; SUMATRIPTAN SUCCINATE 85 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Sumatriptan and Naproxen Sodium — NDC 65862-0928-36," retrieved September 3, 2026, https://drugdashboards.com/drug/65862092836.

Free to cite with attribution — see how the data is put together.